LO/OVRAL FE (ethinyl estradiol; levonorgestrel; ferrous fumarate) by Cadence Neuroscience is ovulation. First approved in 1979.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
LO/OVRAL FE is an oral combination contraceptive containing ethinyl estradiol and levonorgestrel, with added ferrous fumarate for iron supplementation. It prevents pregnancy by suppressing ovulation through hormonal mechanisms. This product is designed for women seeking reliable oral contraception with the added benefit of iron supplementation during the hormone-free interval.
As LOE approaches with moderate competitive pressure (30%), brand defense and transition planning will be critical focus areas with potentially reduced team expansion.
ovulation.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on LO/OVRAL FE offers limited career growth potential given the approaching LOE status and minimal linked job opportunities. Roles will focus on protecting market share, managing generic competition, and navigating product lifecycle transition—valuable defensive strategy experience but not a platform for expansion-focused careers.
Worked on LO/OVRAL FE at Cadence Neuroscience? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.